Lumosa Therapeutics

MENU

Better Therapy Brighter Outlook

About Lumosa

News Center

The US FDA has granted the Orphan Drug Status to Lumosa's LT2003, an anti-tumor targeting fusion protein, for the treatment of pancreatic cancer

Detail

Lumosa received LT5001 IND approval from TFDA for the treatment of uremic pruritus

Detail

Lumosa licensed LT1001 to Jemincare in China

Detail

reSEARCH & DEVELOPMENT

Pipeline NameDisease Treatment

Compound SelectionPre-clinicalPhase 1Phase 2Phase 3NDALaunch

LT1001Post-operative Pain

Launch

LT3001Acute Ischemic Stroke

Phase 2

LT5001Uremic Pruritus

Phase 1

Pre-clinical

Site Map